医療従事者向け がん治療情報解説サイト「 OncoTribune （オンコトリビューン）」に、当院下部消化器外科副部長　賀川義規 医師の2019年欧州臨床腫瘍学会学術集会（ESMO Congress 2019）レポートが掲載されました。

ESMO Congress 2019 FLASH REPORT – 526PD –

TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

https://www.oncotribune.com/report/esmo-co2019/526pd.html ^[1]

ESMO Congress 2019 FLASH REPORT – 525O –

ACHIEVE-2 trial: a randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)

https://www.oncotribune.com/report/esmo-co2019/525o.html ^[2]

ESMO Congress 2019 FLASH REPORT – LBA30_PR –

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration (ID 5478)

https://www.oncotribune.com/report/esmo-co2019/lba30.html ^[3]